Special Issue "Targeting Innate Immunity Cells in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2020).
Interests: immunosenescence; NK cells; T and NK cell-based immunotherapy; cytomegalovirus; leukemia
Advances in the better understanding of the relationship between the immune system and cancer have enabled the development of a broad arsenal of strategies aiming to target different aspects of the immune response for cancer treatment. Natural killer (NK) cells and other innate immunity cells are involved in the defense against tumors and viral infections. Their phenotype and function are strongly affected in patients with cancer. The deeper analysis of these cell alterations not only in cancer but also in other clinical conditions such as viral infection, chronic inflammation, autoimmunity, or ageing will contribute to the design of new therapeutic strategies aiming to modulate NK cell effector functions and to restore their antitumor functionality. In addition, therapeutic antibodies blocking checkpoints in innate immune cells, bispecific linker proteins, or NK cell-based adoptive cellular immunotherapy, including CAR-NK cells, can constitute new weapons to fight cancer. Thus, the aim of this Special Issue is to highlight recent studies on the interaction of NK and other innate immune cells with cancer cells and the potential to modulate innate immunity in cancer therapy.
Prof. Rafael Solana
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.